Luteolin: CAS No:491-70-3 .
Luteolin is a natural flavonoid compound that exists in many plants. It has a variety of pharmacological activities, such as anti-inflammatory, anti-allergic, anti-tumor, anti-bacterial, anti-viral, etc. It is mainly used clinically to relieve cough, expectorant, anti-inflammatory, treat cardiovascular diseases, treat “amyotrophic lateral sclerosis”, SARS , Hepatitis, etc.
Luteoloside also can be called Luteolin-7-O-glucoside ；Cynaroside； 2-(3,4-dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl beta-D-glucopyranoside CAS No.：5373-11-5
Purity is above 98%
Testing method: HPLC
Molecular formula: C21H20O11
Molecular weight: 448.3769
Properties: yellow powder; slightly soluble in water, methanol, ethanol, soluble in hot water, hot methanol and ethanol, insoluble in chloroform, ether, benzene, petroleum ether and other small polar solvents.
Melting point: 254-256°C.
Ultraviolet maximum absorption: 255,350 (nm).
Common uses :
1. Respiratory system effects: Luteolin has a strong respiratory tract bactericidal effect. It is the main effective ingredient in the treatment of tracheitis in Qinglan, a unique medicinal material in Xinjiang.
2. Cardiovascular effects: Reduce the role of cholesterol in atherosclerosis and enhance the relaxation of capillaries.
3. Central system effect: In experiments, it was found that luteolin can relieve benzene. Honeysuckle is a traditional Chinese medicinal material in my country.
It has a wide range of functions and has strong bactericidal, anti-inflammatory, antipyretic and analgesic effects. Honeysuckle belongs to the family Lonicerae. According to the provisions of the 2005 Chinese Pharmacopoeia, the iconic components in honeysuckle are chlorogenic acid and luteolin, and whether it contains luteolin is the main chemical that distinguishes genuine honeysuckle from the same family of Lonicera and Honeysuckle. The index is also the main reason for the difference in efficacy between genuine honeysuckle and Lonicera japonica plants in the same family.
Post time: Mar-25-2021